Jane Street Group LLC Has $681,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Jane Street Group LLC lowered its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 48.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 81,883 shares of the company's stock after selling 75,676 shares during the period. Jane Street Group LLC's holdings in Amneal Pharmaceuticals were worth $681,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Rothschild Investment LLC acquired a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at $26,000. Gladius Capital Management LP bought a new position in Amneal Pharmaceuticals in the third quarter valued at about $37,000. DekaBank Deutsche Girozentrale acquired a new stake in Amneal Pharmaceuticals in the second quarter worth about $42,000. Xponance Inc. bought a new stake in Amneal Pharmaceuticals during the 2nd quarter worth about $65,000. Finally, Quest Partners LLC acquired a new position in Amneal Pharmaceuticals during the 3rd quarter valued at about $84,000. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Price Performance

AMRX traded up $0.06 during mid-day trading on Friday, hitting $7.82. The stock had a trading volume of 778,163 shares, compared to its average volume of 1,078,937. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.01 and a 1-year high of $9.48. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of -11.50 and a beta of 1.10. The stock's fifty day simple moving average is $8.28 and its 200-day simple moving average is $8.00.

Insider Buying and Selling

In related news, SVP Jason B. Daly sold 43,657 shares of the business's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the completion of the transaction, the senior vice president now directly owns 13,665 shares in the company, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 26.56% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AMRX. Piper Sandler boosted their price target on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. StockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price target on the stock in a research report on Friday, September 6th. Finally, Truist Financial upped their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a report on Wednesday, October 2nd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.